Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Phase 3 TRIUMPH Program (Ongoing) - LIVER AS SECONDARY ENDPOINT Status: Currently ongoing, results expected 2026 TRIUMPH-4 (Completed December 2025): Primary endpoints: Weight loss + osteoarthritis pain Results: 28.7% weight loss at 68 weeks Liver outcomes: Secondary/exploratory endpoints TRIUMPH-2 (Ongoing, expected 2026): Weight loss in obesity + type 2 diabetes Liver outcomes: Secondary endpoints (liver enzymes, possibly imaging) Key Point: TRIUMPH Phase 3 trials are NOT primarily liver-focused
10.1371/journal.pone.0248103 71 LautatzisM
Carnisure Syrup works by helping the body convert fat into energy and improving low carnitine levels
A more detailed look at the numbers makes the clinical importance easier to see
There are GLP-1 clinical trials focused on both obesity and type 2 diabetes
US$ 28.34
US$ 23.10
US$ 25.76
US$ 21.36
US$ 29.48
US$ 22.70
US$ 23.69
US$ 21.87
US$ 29.10
US$ 20.20
US$ 29.22
US$ 25.23
US$ 26.99
